|
|
Identification of optimum spectacle prescriptions for patients with Down syndrome |
| 5R01EY024590-08 |
|
NEI |
2022 |
|
|
Applications of high resolution fMRI in ultra-high field (7T) in revealing developmental disorders underlying amblyopia |
| 5R01EY030434-03 |
|
NEI |
2022 |
|
|
Neuropsychological Profiles and Risk for Dementia-Related Disease in Mothers of Children with Autism Spectrum Disorder |
| 1F32AG079615-01 |
|
NIA |
2022 |
|
|
Iron Metabolism in Ts65Dn mice, a Model of Down syndrome |
| 1R15AG077421-01 |
|
NIA |
2022 |
|
|
Restoration of proteostasis to address co-occurring conditions in Down Syndrome |
| 1RF1AG078969-01 |
|
NIA |
2022 |
|
|
The role of APP in neurogenesis and AD in Down syndrome |
| 1RF1AG079002-01 |
|
NIA |
2022 |
|
|
Cell and Network Disruptions and Associated Pathogenenesis in Tauopathy and Down Syndrome |
| 3R01AG064579-03S1 |
|
NIA |
2022 |
|
|
Down Syndrome: Toward Optimal Trajectories and Health Equity using Medicaid Analytic eXtract (DS -TO-THE-MAX) |
| 3R01AG073179-01S1 |
|
NIA |
2022 |
|
|
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS) |
| 3U19AG068054-02S2 |
|
NIA |
2022 |
|
|
Treating with Gamma-Secretase Modulators to Prevent Neurodegeneration in Mouse Models of Down Syndrome and Alzheimer Disease |
| 5R01AG055523-05 |
|
NIA |
2022 |